Diagnostic Value Of CT For Breast Cancer Chemotherapy-related Fatty Liver And Its Relationship With Liver Function

Objective: To explore the diagnostic value of CT for breast cancer chemotherapy-related fatty liver,to understand the characteristics of chemotherapy-related fatty liver,and to explore the relationship between chemotherapy-related fatty liver and liver function enzyme index changes.Materials and methods: The patients were collected from the First Affiliated Hospital of Guangxi Medical University from June 2014 to June 2018 and diagnosed as 300 patients with breast cancer.All of them were female patients,aged 31-71 years,with an average age of 50.11±9.11 years.BMI: 24.40 ± 3.70,all patients completed radical mastectomy or modified radical surgery in parallel with standard systemic chemotherapy for at least 4 weeks.All patients underwent liver function tests and liver CT examination before chemotherapy.Before the first chemotherapy,the liver function of the patients was normal and the liver imaging was normal.The changes of liver CT and liver function were compared before and after chemotherapy.Tumor TNM stage was from I to III,and there was no history of drinking or smoking.To collect the age,body mass index(BMI),breast cancer pathological type,tumor TNM stage,chemotherapy program liver CT changes,liver function index changes in breast cancer patients during chemotherapy,establish a database,apply SPSS22.0 statistical software Statistical analysis was performed on various imaging data and clinical data.The test standard was ?=0.05.When P<0.05,the difference was statistically significant.The CT findings and characteristics of chemotherapy-related chemotherapy-related fatty liver were analyzed,and the relationship between it and liver function enzyme index was analyzed.At the same time,the risk factors of chemotherapy-related fatty liver in breast cancer patients were compared and analyzed.Results: 1.Univariate analysis showed that the difference of chemotherapy regimen was the risk factor of chemotherapy-related liver injury in breast cancer patients.The incidence of fatty liver was as follows: anthracycline sequential paclitaxel,anthracycline combined with paclitaxel,anthracycline Class,no anthracycline scheme.2.Among the 300 patients with breast cancer,92 patients developed fatty liver.The first time to develop fatty liver was 2 cycles after chemotherapy.The highest incidence of fatty liver was 3 cycles after chemotherapy.There were 32 cases,accounting for 34.7%.After the end of thehalf-year to 1 year review,53 patients with fatty liver reduced or even subsided,there are still 39 patients with persistent fatty liver.3.Among the 300 patients,92 had chemotherapy-related fatty liver,accounting for 30.66%,of which 44(47.83%),28(30.43%),and 20(21.74%)were mild,moderate,and severe,respectively).4.Among the 92 patients with chemotherapy-related fatty liver,the mild,moderate,and severe fatty liver three groups were significantly different from the control group(no fatty liver group)(P<0.05).There were significant differences in CT values between different groups of fatty liver in different degrees(P<0.05).5.Among the 92 patients with fatty liver,58 patients had elevated liver function indexes.In the mild,moderate,and severe groups,22 patients,16 patients,and 20 patients had abnormal liver function indexes.There were significant differences in liver function indexes between patients with fatty liver before and after chemotherapy(P<0.05).6.The highest proportion of abnormal liver function indexes in each group was in the severe group,and the lowest proportion was in the mild group,suggesting that the liver function damage in the severe fatty liver group after chemotherapy was more severe than that in other mild and moderate groups.7.There were significant differences in ALT and AST between different degrees of fatty liver(P<0.05).There were significant differences in ALT and AST between the severe group and the mild group and the moderate group(P<0.05).The difference between the GGT group and the severe group was statistically significant(P<0.05).Conclusions: 1.Breast cancer patients can cause fatty liver afterchemotherapy.CT can quantitatively diagnose and dynamically monitor the degree of chemotherapy-related fatty liver in breast cancer patients.2.chemotherapy occurs in the first two cycles after chemotherapy,the peak incidence of fatty liver is 3 cycles after chemotherapy,fatty liver can be resolved after stopping the drug.3.There is a correlation between the degree of chemotherapy-related fat and the increase of ALT and AST index values,and the increase of ALT and AST is more obvious as the degree of fatty liver is aggravated.4.the incidence of liver damage in the chemotherapy regimen anthracycline sequential paclitaxel chemotherapy regimen > anthracycline combined with paclitaxel chemotherapy regimen > anthracycline chemotherapy.